Aldosterone and the heart: From basic research to clinical evidence

Hormone and Metabolic Research

Volumn 44, Issue 3, 2012, Pages 181-187

  Catena, C ^a   Colussi, G ^a   Marzano, L ^a   Sechi, L A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

arrhythmia; atrial fibrillation; essential hypertension; heart failure; mineralocorticoid receptor antagonists; primary aldosteronism; spironolactone

Indexed keywords

ALDOSTERONE; CANRENONE; ENALAPRIL; EPLERENONE; PLACEBO; SPIRONOLACTONE;

DIASTOLIC HEART FAILURE; DRUG DOSE TITRATION; ESSENTIAL HYPERTENSION; EXPERIMENTAL MODEL; HEART; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; NONHUMAN; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; SYSTOLIC HEART FAILURE;

ALDOSTERONE; ANIMALS; HEART; HEART DISEASES; HUMANS; HYPERALDOSTERONISM;

ANIMALIA;

EID: 84858002935     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1291318     Document Type: Review

References (59)

1. Pitt B, Zannad F, Remme W J, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect ofspironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717 (Pubitemid 29407370)
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321 (Pubitemid 36384098)
3. Zannad F, McMurray JJ V, Krum H, van Veldhuisen D J, Swedberg K, Shi H, Vincent J, Pocock S J, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
4. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman A, Bonvalet J P. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-β-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-182
5. Marney A M, Brown N J. Aldosterone and end-organ damage. Clin Sci 2007; 113: 267-278 (Pubitemid 47372685)
6. Brilla C G, Weber K T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901 (Pubitemid 23002899)
7. Rocha R, Rudolph A E, Frierdich G E, Nachowiak D A, Kekec B K, Blomme E A, McMahon E G, Delyani J A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810 (Pubitemid 35217013)
8. Martinez D V, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, Williams G H, Adler G K. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002; 39: 614-618 (Pubitemid 34165193)
9. Neves M F, Amiri F, Virdis A, Diep Q N, Schiffrin E L; CIHR Multidisciplinary Research Group on Hypertension. Role ofaldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005; 83: 999-1006 (Pubitemid 43385544)
10. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salttreated rats: effects ofeplerenone. Circulation 2002; 106: 2848-2853 (Pubitemid 35396986)
11. Cachofeiro V, Miana M, de Las Heras N, Martín-Fernández B, Ballesteros S, Fernández-Tresguerres J, Lahera V. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008; 109: 331-335
12. Mohammed S F, Ohatani T, Korinek J, Lam C S, Larsen K, Simari R D, Valencik M L, Burnett J C Jr, Redfield M M. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic" effects. Circulation 2010; 122: 378-379
13. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level ofaldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects ofmineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007; 292: R954-R964
14. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms ofeplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-679 (Pubitemid 43740237)
15. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden M R, Karuparthi P R, Qazi M, Morris E M, Cooper S A, Link C D, Stump C, Hay M, Ferrario C, Sowers J R. Mineralocorticoid receptor blockade attenuates chronic overexpression ofthe renin-angiotensin-aldosterone system stimulation ofNADPH oxidase and cardiac remodeling. Endocrinology 2007; 148: 3773-3780 (Pubitemid 47105865)
16. Habibi J, DeMarco V G, Ma L, Pulakat L, Rainey W E, Whaley-Connell A T, Sowers J R. Mineralocorticoid receptor blockade improve diastolic function independent ofblood pressure reduction in a transgenic model ofRAAS overexpression. Am J Physiol Heart Circ Physiol 2002; 300: H1484-H1491
17. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G, Bauersachs J. Deletion ofcardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011; 123: 400-408
18. Reil J C, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Munz B M, Muller P, Steendijk P, Reil G H, Allessie M A, Bohm M, Neuberger H R. Aldosterone promotes atrial fibrillation. Eur Heart J 2011, Aug 4 [Epub ahead ofprint]
19. Jaffe I Z, Mendelsohn M E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cell. Circ Res 2005; 96: 643-650 (Pubitemid 40478331)
20. Benard L, Milliez P, Ambroisine M L, Messaoudi S, Samuel J L, Delcayre C. Effects ofaldosterone on coronary function. Pharmacol Rep 2009; 61: 58-66
21. Nguyen Dinh Cat A, Griol Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010; 24: 2454-2463
22. Favre J, Gao J, Zhang A D, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B, Escoubet B, Thuillez C, Jaisser F, Richard V. Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol 2011; 300: H2035-H2043
23. Conn J W, KnopfR F, Nesbit R M. Clinical characteristics ofprimary aldosteronism from an analysis of145 cases. Am J Surg 1964; 107: 159-172
24. Gomez-Sanchez C E, Rossi G P, Fallo F, Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Horm Metab Res 2010; 42: 374-381
25. Laragh J H. Vasoconstriction-Volume analysis for understanding and treating hypertension: the use ofrenin and aldosterone profiles. Am J Med 1973; 55: 261-274
26. Funder J W. Is aldosterone bad for the heart? Trends Endocrinol Metab 2004; 15: 139-142 (Pubitemid 38510491)
27. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, Boari G E, Zani F, Miclini M, Tiberio G A, Giulini S M, Rosei C A, Bianchi R, Agabiti Rosei E. Changes in extracellular matrix in subcutaneous small resistance arteries ofpatients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-2642 (Pubitemid 44024630)
28. Catena C, Colussi G L, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi L A. Relationships ofplasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2007; 2: 722-731
29. Rossi G P, Sechi L A, Giacchetti G, Ronconi V, Strazzullo P, Funder J W. Primary aldosteronism: cardiovascular, renal, and metabolic implications. Trends Endocrinol Metab 2008; 19: 88-90 (Pubitemid 351442920)
30. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi L A. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463 (Pubitemid 44402119)
31. Sechi L A, Catena C. The dual role ofthe kidney in primary aldosteronism: key determinant in rescue from volume expansion and persistence ofhypertension. Am J Kidney Dis 2009; 54: 594-597
32. Sechi L A, Colussi G L, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010; 12: 1253-1260
33. Strauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimsky J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19: 909-914 (Pubitemid 46106987)
34. Holaj R, Zelinka T, Wichterle D, Petrák O, Strauch B, Widimsky J Jr. Increased intima media thickness ofthe common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451-1457 (Pubitemid 46918833)
35. Rossi G P, Rossi A, Zanin L, Calabró A, Crepaldi G, Pessina A C. Prevalence ofextracranial carotid artery lesions at duplex in primary aldosteronism. Am J Hypertens 1993; 6: 8-14 (Pubitemid 23055798)
36. Muiesan M L, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534
37. Rossi G P, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina A C. Excess aldosterone is associated with alterations ofmyocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-27 (Pubitemid 34755974)
38. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi L A. Long-term cardiac effects ofadrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918 (Pubitemid 350287534)
39. Cicala M, Cesari M, Patalano A, Iacobone M, Mariniello B, Mantero F. Treatment ofprimary aldosteronism: short and middle-term effects ofmedical and surgical therapy in primary hyperaldosteronism: experience of45 cases. J Hypertens 2010; 28 (e-Supplement A) : 305
40. Milliez P, Girerd X, Plouin P F, Blacher J, Safar M E, Mourad J J. Evidence for an increased rate ofcardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248 (Pubitemid 40523144)
41. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi L A. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
42. Born-Frontsberg E, Reincke M, Rump L C, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M; Participants ofthe German Conn's Registry. Cardiovascular and cerebrovascular comorbidities ofhypokalemic and normokalemic primary aldosteronism: results ofthe German Conn's Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
43. Steichen O, Amar L, Plouin P F. Cardiovascular complications in patients with primary hyperaldosteronism: a controlled cross-sectional study. J Hypertens 2010; 28 (e-Supplement A1) : e-301
44. Catena C, Colussi G L, Di Fabio A, Valeri M, Marzano L, Uzzau A, Sechi L A. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010; 42: 440-445
45. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips R A, Roniker B, Kleiman J, Krazuse S, Burns D, Williams GH. Effects ofeplerenone, enalalpril, and eplerenone/enelapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838 (Pubitemid 37296092)
46. Mottram P M, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect ofaldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558-565 (Pubitemid 39031173)
47. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd S G, Oparil S, Husain A, Dell'Italia L J, Calhoun DA. Rapid reversal ofleft ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension 2010; 55: 1137-1142
48. Sechi L A, Colussi G L, Catena C. Hyperaldosteronism and left ventricular hypertrophy. Hypertension 2010; 56: e26
49. Boccanelli A, Mureddu G F, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni A P, Masson S, Vanasia M, De Simone G. Anti-remodelling effects ofcanrenone in patients with mild chronic heart failure (AREA IN-CHfstudy): final results. Eur J Heart Failure 2009; 11: 68-76
50. Vizzardi E, D'Aloia A, Giubbini R, Bordonali T, Bugatti S, Pezzali N, Romeo A, Dei Cas A, Metra M, Dei Cas L. Effects ofspironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 2010; 106: 1292-1296
51. Mak G J, Ledwidge M T, Watson C J, Phelan D M, Dawkins I R, Murphy N F, Patle A K, Baugh J A, McDonald K M. Natural history ofmarkers ofcollagen turnover in patients with early diastolic dysfunction and impact ofeplerenone. J Am Coll Cardiol 2009; 54: 1674-1682
52. Edwards N C, Ferro C J, Kirkwood H, Chue C D, Young A A, Stewart P M, Steeds R P, Townsends J N. Effect ofspironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010; 106: 1505-1511
53. Schaer B A, Schneider C, Jick S S, Conen D, Osswald S, Meier CR. Risk for incident Afin patients receiving antihypertensive drugs. Ann Intern Med 2010; 152: 78-84
54. Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, Kazimierska B, Wozniak J, Zareba W, Szwed H. Effect combined spironolactone-β blocker±enalapril treatment on occurrence ofsymptomatic atrial fibrillation episodes in patients with a history ofparoxysmal atrial fibrillation (SPIR-Afstudy). Am J Cardiol 2010; 206: 1609-1614
55. Gao X, Peng L, Adhikari C M, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007; 13: 170-177 (Pubitemid 46591953)
56. Amir O, Amir R E, Paz H, Mor R, Sagiy M, Lewis B S. Aldosterone synthase gene polymorphism as a determinant ofatrial fibrillation in patients with heart failure. Am J Cardiol 2008; 102: 326-329
57. Tsai C T, Chaing fT, Tseng C D, Hwang J J, Kuo K T, Wu C K, Yu C C, Wang Y C, Lai L P, Lin J L. Increased expression ofmineralocorticoid receptor in human atrial fibrillation and a cellular model ofatrial fibrillation. J Am Coll Cardiol 2010; 55: 758-770
58. Korantzopoulos P, Goudevenos J A. Aldosterone signaling in atrial fibrillation. Another piece in the puzzle ofatrial remodeling. J Am Coll Cardiol 2010; 55: 771-773
59. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect ofaldosterone antagonists for ventricular arrhythmia: a metaanalysis. Clin Cardiol 2010; 9: 572-577